BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 26139392)

  • 1. Gene-asbestos interaction in malignant pleural mesothelioma susceptibility.
    Tunesi S; Ferrante D; Mirabelli D; Andorno S; Betti M; Fiorito G; Guarrera S; Casalone E; Neri M; Ugolini D; Bonassi S; Matullo G; Dianzani I; Magnani C
    Carcinogenesis; 2015 Oct; 36(10):1129-35. PubMed ID: 26139392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Iron signature in asbestos-induced malignant pleural mesothelioma: A population-based autopsy study.
    Crovella S; Bianco AM; Vuch J; Zupin L; Moura RR; Trevisan E; Schneider M; Brollo A; Nicastro EM; Cosenzi A; Zabucchi G; Borelli V
    J Toxicol Environ Health A; 2016; 79(3):129-41. PubMed ID: 26818092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential mutation profiles and similar intronic TP53 polymorphisms in asbestos-related lung cancer and pleural mesothelioma.
    Andujar P; Pairon JC; Renier A; Descatha A; Hysi I; Abd-Alsamad I; Billon-Galland MA; Blons H; Clin B; Danel C; Debrosse D; Galateau-Sallé F; Housset B; Laurent-Puig P; Le Pimpec-Barthes F; Letourneux M; Monnet I; Régnard JF; Validire P; Zucman-Rossi J; Jaurand MC; Jean D
    Mutagenesis; 2013 May; 28(3):323-31. PubMed ID: 23435014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic variants associated with increased risk of malignant pleural mesothelioma: a genome-wide association study.
    Matullo G; Guarrera S; Betti M; Fiorito G; Ferrante D; Voglino F; Cadby G; Di Gaetano C; Rosa F; Russo A; Hirvonen A; Casalone E; Tunesi S; Padoan M; Giordano M; Aspesi A; Casadio C; Ardissone F; Ruffini E; Betta PG; Libener R; Guaschino R; Piccolini E; Neri M; Musk AW; de Klerk NH; Hui J; Beilby J; James AL; Creaney J; Robinson BW; Mukherjee S; Palmer LJ; Mirabelli D; Ugolini D; Bonassi S; Magnani C; Dianzani I
    PLoS One; 2013; 8(4):e61253. PubMed ID: 23626673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pleural mesothelioma and lung cancer: the role of asbestos exposure and genetic variants in selected iron metabolism and inflammation genes.
    Celsi F; Crovella S; Moura RR; Schneider M; Vita F; Finotto L; Zabucchi G; Zacchi P; Borelli V
    J Toxicol Environ Health A; 2019; 82(20):1088-1102. PubMed ID: 31755376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential Susceptibility of Human Pleural and Peritoneal Mesothelial Cells to Asbestos Exposure.
    Dragon J; Thompson J; MacPherson M; Shukla A
    J Cell Biochem; 2015 Aug; 116(8):1540-52. PubMed ID: 25757056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative proteomic analysis of malignant pleural mesothelioma evidences an altered expression of nuclear lamin and filament-related proteins.
    Giusti L; Da Valle Y; Bonotti A; Donadio E; Ciregia F; Ventroni T; Foddis R; Giannaccini G; Guglielmi G; Cristaudo A; Lucacchini A
    Proteomics Clin Appl; 2014 Apr; 8(3-4):258-68. PubMed ID: 24415579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating microRNAs found dysregulated in ex-exposed asbestos workers and pleural mesothelioma patients as potential new biomarkers.
    Bononi I; Comar M; Puozzo A; Stendardo M; Boschetto P; Orecchia S; Libener R; Guaschino R; Pietrobon S; Ferracin M; Negrini M; Martini F; Bovenzi M; Tognon M
    Oncotarget; 2016 Dec; 7(50):82700-82711. PubMed ID: 27716620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Germline mutations in DNA repair genes predispose asbestos-exposed patients to malignant pleural mesothelioma.
    Betti M; Casalone E; Ferrante D; Aspesi A; Morleo G; Biasi A; Sculco M; Mancuso G; Guarrera S; Righi L; Grosso F; Libener R; Pavesi M; Mariani N; Casadio C; Boldorini R; Mirabelli D; Pasini B; Magnani C; Matullo G; Dianzani I
    Cancer Lett; 2017 Oct; 405():38-45. PubMed ID: 28687356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An asbestos-exposed family with multiple cases of pleural malignant mesothelioma without inheritance of a predisposing BAP1 mutation.
    Cheung M; Kadariya Y; Pei J; Talarchek J; Facciolo F; Visca P; Righi L; Cozzi I; Testa JR; Ascoli V
    Cancer Genet; 2015 Oct; 208(10):502-7. PubMed ID: 26364129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peripheral Blood DNA Methylation as Potential Biomarker of Malignant Pleural Mesothelioma in Asbestos-Exposed Subjects.
    Guarrera S; Viberti C; Cugliari G; Allione A; Casalone E; Betti M; Ferrante D; Aspesi A; Casadio C; Grosso F; Libener R; Piccolini E; Mirabelli D; Dianzani I; Magnani C; Matullo G
    J Thorac Oncol; 2019 Mar; 14(3):527-539. PubMed ID: 30408567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BAP1 protein is a progression factor in malignant pleural mesothelioma.
    Arzt L; Quehenberger F; Halbwedl I; Mairinger T; Popper HH
    Pathol Oncol Res; 2014 Jan; 20(1):145-51. PubMed ID: 23963927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasmatic extracellular vesicle microRNAs in malignant pleural mesothelioma and asbestos-exposed subjects suggest a 2-miRNA signature as potential biomarker of disease.
    Cavalleri T; Angelici L; Favero C; Dioni L; Mensi C; Bareggi C; Palleschi A; Rimessi A; Consonni D; Bordini L; Todaro A; Bollati V; Pesatori AC
    PLoS One; 2017; 12(5):e0176680. PubMed ID: 28472171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Malignant and non-malignant asbestos-related pleural and lung disease: 10-year follow-up study.
    Cvitanović S; Znaor L; Konsa T; Ivancević Z; Perić I; Erceg M; Vujović M; Vuković J; Beg-Zec Z
    Croat Med J; 2003 Oct; 44(5):618-25. PubMed ID: 14515425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of two BRM promoter polymorphisms and smoking status with malignant pleural mesothelioma risk and prognosis.
    Lee MJ; Kuehne N; Hueniken K; Liang S; Rai S; Sorotsky H; Herman M; Shepshelovich D; Bruce J; Liang M; Patel D; Cheng D; Chen Z; Eng L; Brown MC; Cho J; Leighl NB; de Perrot M; Reisman D; Xu W; Bradbury PA; Liu G
    Mol Carcinog; 2019 Nov; 58(11):1960-1973. PubMed ID: 31355511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Five years update on relationships between malignant pleural mesothelioma and exposure to asbestos and other elongated mineral particles.
    Andujar P; Lacourt A; Brochard P; Pairon JC; Jaurand MC; Jean D
    J Toxicol Environ Health B Crit Rev; 2016; 19(5-6):151-172. PubMed ID: 27705546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased Standardised Incidence Ratio of Malignant Pleural Mesothelioma in Taiwanese Asbestos Workers: A 29-Year Retrospective Cohort Study.
    Lin CK; Chang YY; Wang JD; Lee LJ
    Biomed Res Int; 2015; 2015():678598. PubMed ID: 26290869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physician requests by patients with malignant pleural mesothelioma in Japan.
    Nagamatsu Y; Oze I; Aoe K; Hotta K; Kato K; Nakagawa J; Hara K; Kishimoto T; Fujimoto N
    BMC Cancer; 2019 Apr; 19(1):383. PubMed ID: 31023248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting angiogenesis for patients with unresectable malignant pleural mesothelioma.
    Tsao A; Nakano T; Nowak AK; Popat S; Scagliotti GV; Heymach J
    Semin Oncol; 2019 Apr; 46(2):145-154. PubMed ID: 31280996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Malignant pleural mesothelioma incidence and survival in the Republic of Ireland 1994-2009.
    Jennings CJ; Walsh PM; Deady S; Harvey BJ; Thomas W
    Cancer Epidemiol; 2014 Feb; 38(1):35-41. PubMed ID: 24394956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.